Citadel Advisors
INDP icon

Citadel Advisors’s Indaptus Therapeutics INDP Stock Holding History

Citadel Advisors’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,018
Closed -$71K – 14251
2026
Q1 		$71K Buy
+39,018
New +$83.7K ﹤0.01% 12243
2024
Q4 		– Sell
-550
Closed -$19.1K – 14913
2024
Q3 		$19.1K Sell
550
-243
-31% -$11.9K ﹤0.01% 12805
2024
Q2 		$47.1K Buy
+793
New +$52.6K ﹤0.01% 11832
2024
Q1 		– Sell
-590
Closed -$29.2K – 14999
2023
Q4 		$29.2K Buy
+590
New +$37.1K ﹤0.01% 12287
2022
Q4 		– Sell
-389
Closed -$24K – 15152
2022
Q3 		$24K Buy
+389
New +$30.3K ﹤0.01% 12003
2021
Q4 		– Sell
-508
Closed -$111K – 14253
2021
Q3 		$111K Buy
508
+398
+362% +$115K ﹤0.01% 12744
2021
Q2 		$43K Sell
110
-90
-45% -$39.6K ﹤0.01% 13388
2021
Q1 		$98K Sell
200
-215
-52% -$113K ﹤0.01% 12495
2020
Q4 		$160K Buy
415
+392
+1,704% +$171K ﹤0.01% 9901
2020
Q3 		$13K Sell
23
-109
-83% -$80.1K ﹤0.01% 9922
2020
Q2 		$84K Buy
132
+78
+144% +$48.2K ﹤0.01% 9086
2020
Q1 		$23K Buy
54
+36
+200% +$27.2K ﹤0.01% 9263
2019
Q4 		$20K Sell
18
-20
-53% -$27.6K ﹤0.01% 8937
2019
Q3 		$63K Buy
+38
New +$113K ﹤0.01% 8647

Other funds holding INDP

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's INDP Position: Q2 2026 in Review

Citadel Advisors sold out of Indaptus Therapeutics (INDP) in Q2 2026, closing a stake of 39,018 shares — an estimated $71K sold.

Citadel Advisors first reported a position in INDP in Q3 2019 and held it in 14 quarters. The position peaked at $160K in Q4 2020. 9 funds tracked by Wall St. Rank hold INDP as of Q2 2026.

  • Citadel Advisors reported no remaining Indaptus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 39,018 Indaptus Therapeutics shares in Q2 2026, an estimated $71K.
  • Citadel Advisors first reported a position in Indaptus Therapeutics in Q3 2019 and held it in 14 quarters.
  • Citadel Advisors's Indaptus Therapeutics position peaked at $160K in Q4 2020.
  • 9 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.